In re: Bayer Corporation Combination Aspirin Products Marketing and Sales Practices Litigation

Photo credit: Wikimedia

Docket number: No. 09-md-2023 (BMC) (JMA), (E.D.N.Y. Apr. 11, 2013)

As a result of the Center’s objection, the parties modified the settlement to increase direct payments to the class by over $5.8M. Our second objection resulted in a third-party recipient of settlement funds that better suited the purpose of the litigation.

Case Documents

Description
Apr 11, 2013 ORDER of the District Court

 

Search this website Type then hit enter to search